Wellington Partners
Immatics and Celgene have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. Immatics may develop T-Cell Receptor Engineered T-cell Therapy (TCR-T) programs against solid tumor targets discovered with Immatics’ XPRESIDENT® technology. Programs would utilize proprietary T-Cell Receptors (TCRs) identified by Immatics’ XCEPTOR® TCR discovery and engineering platform. If Immatics develops programs against the TCR-T targets, Immatics will be responsible for the development and validation of these programs through lead candidate stage, at which time Celgene may exercise opt-in rights and assume sole responsibility for further worldwide development, manufacturing and commercialization of the TCR-T-cell therapies.
Themis announced today a research collaboration and exclusive license agreement with MSD for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform. Under the terms of the agreement, Themis will develop vaccine candidates against an undisclosed disease target. MSD will provide research funding and make an equity investment in Themis. In addition, Themis will be eligible to receive development and sales milestone payments up to the potential value of approx. USD 200 million as well as royalties on approved products from the collaboration.
Wellington Partners today announced the final close of its fifth-generation fund Wellington Partners Life Science Fund V (WPLS-V). The fund closed at EUR 210 million, making it the largest life science dedicated fund raised by Wellington Partners to date. WPLS-V will build a portfolio of approximately 15-20 companies, ranging in focus from novel biotechnology platforms, new therapeutics and medical devices, including selected investments in diagnostics and digital medicine. All of the fund’s investments will target substantial improvements to current medical practice for the benefit of patients, practitioners, and payors alike.
Page 5 of 25
